Clinical Trials Browser

Interventional × TTI-621 × Clear all

NCT05507541 2025-08-29

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

10 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04996004 2024-12-11

TTI-621-03

Phase 2 Terminated

76 enrolled 53 charts

Sarcoma

Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Phase 1 Terminated

249 enrolled 43 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Phase 1 Terminated

56 enrolled

BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell